Spyre Therapeutics (SYRE) Stock Price, News & Analysis

Company Overview

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn’s disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.

Spyre’s pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A). Its research approach emphasizes antibody engineering, with the goal of developing therapies that may offer durable activity, convenient dosing, and potential use in combination treatment regimens. The company’s programs remain in clinical development and are subject to ongoing evaluation for safety and effectiveness.

The company was formed through a transaction involving Aeglea BioTherapeutics and Spyre Therapeutics and began trading under the name Spyre Therapeutics and the Nasdaq symbol SYRE in 2023. Spyre is headquartered in the United States and conducts its drug discovery and development activities through research, clinical, and corporate operations. Its leadership includes Chief Executive Officer and President Cameron Turtle, Ph.D.

Key Stats

• Today's Range: $76.87 to $80.88
• 50-Day Range: $78.63 to $108.92
• 52-Week Range: $21.15 to $110.18
• Volume: 1.15 million shs
• Average Volume: 1.14 million shs
• Market Capitalization: $8.16 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $110.40
• Consensus Rating: Moderate Buy

Spyre Therapeutics Stock Analysis - MarketRank™

Spyre Therapeutics scored higher than 54% of companies evaluated by MarketBeat, and ranked 498th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Spyre Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.94, and is based on 2 strong buy ratings, 13 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Spyre Therapeutics has a consensus price target of $110.40, representing about 37.8% upside from its current price of $80.10.

Amount of Analyst Coverage

Spyre Therapeutics has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Spyre Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.67) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spyre Therapeutics is -41.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spyre Therapeutics is -41.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Spyre Therapeutics has a P/B Ratio of 11.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.33% of the float of Spyre Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Spyre Therapeutics has a short interest ratio ("days to cover") of 8.89.

Change versus previous month

Short interest in Spyre Therapeutics has recently increased by 5.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spyre Therapeutics does not currently pay a dividend.

Dividend Growth

Spyre Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.69

News Sentiment

Spyre Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Spyre Therapeutics this week, compared to 5 articles on an average week.

MarketBeat Follows

Only 1 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Spyre Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,903,193.00 in company stock.

Percentage Held by Insiders

15.69% of the stock of Spyre Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SYRE
• Previous Symbol: NASDAQ:SYRE
• CIK: 1636282
• Web: www.spyre.com
• Phone: (617) 651-5940
• Fax: 512-872-5121
• Employees: 112
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Spyre Therapeutics: $110.40
• High Price Target: $130.00
• Low Price Target: $80.00
• Potential Upside/Downside: +37.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.94
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.95)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$155.20 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -30.74%
• Return on Assets: -22.23%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.53
• Quick Ratio: 18.53

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.21 per share
• Price / Book: 11.11

Miscellaneous

• Outstanding Shares: 101,906,000
• Free Float: 85,917,000
• Market Cap: $8.16 billion
• Optionable: Optionable
• Beta: 3.10